Loading...
Loading...
Sterne Agee remains Neutral rated with a $43 target price on Carter's
CRI as it expects the company to beat expectations, but valuation suggests staying on the sidelines.
Sterne Agee notes, "While Carter's is poised to benefit from lower cotton costs starting in Q3, we maintain our Neutral rating due to valuation levels. Our target is $43 based upon 14.1xour FY13 EPS estimate, in line with its historic forward valuation."
CRI closed at $40.43 a share on Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in